Department of Surgery, Cheil General Hospital & Women's Health Care Center, Catholic Kwandong University College of Medicine, Seoul, Korea.
Department of Pathology, CHA Gangnam Medical Center, CHA University, Seoul, Korea.
J Breast Cancer. 2014 Sep;17(3):207-18. doi: 10.4048/jbc.2014.17.3.207. Epub 2014 Sep 30.
14-3-3 sigma (σ) is considered to be an important tumor suppressor and decreased expression of the same has been reported in many malignant tumors by hypermethylation at its promoter or ubiquitin-mediated proteolysis by estrogen-responsive ring finger protein (Efp). In this study, we investigated the significance of 14-3-3 σ expression in human breast cancer and its regulatory mechanism.
Efp was silenced using small interfering RNA (siRNA) in the MCF-7 breast cancer cell line in order to examine its influence on the level of 14-3-3 σ protein. The methylation status of the 14-3-3 σ promoter was also evaluated by methylation-specific polymerase chain reaction (PCR). The expression of Efp and 14-3-3 σ in 220 human breast carcinoma tissues was assessed by immunohistochemistry. Other clinicopathological parameters were also evaluated.
Silencing Efp in the MCF-7 breast cancer cell line resulted in increased expression of 14-3-3 σ. The Efp-positive human breast cancers were more frequently 14-3-3 σ-negative (60.5% vs. 39.5%). Hypermethylation of 14-3-3 σ was common (64.9%) and had an inverse association with 14-3-3 σ positivity (p=0.072). Positive 14-3-3 σ expression was significantly correlated with poor prognosis: disease-free survival (p=0.008) and disease-specific survival (p=0.009).
Our data suggests that in human breast cancer, the regulation of 14-3-3 σ may involve two mechanisms: ubiquitin-mediated proteolysis by Efp and downregulation by hypermethylation. However, the inactivation of 14-3-3 σ is probably achieved mainly by hypermethylation. Interestingly, 14-3-3 σ turned out to be a very significant poor prognostic indicator, which is in contrast to its previously known function as a tumor suppressor, suggesting a different role of 14-3-3 σ in breast cancer.
14-3-3σ(σ)被认为是一种重要的肿瘤抑制因子,其在许多恶性肿瘤中表达降低,这是由于其启动子的高甲基化或雌激素反应性环指蛋白(Efp)介导的泛素化蛋白酶体降解所致。在本研究中,我们研究了 14-3-3σ在人乳腺癌中的表达意义及其调控机制。
用小干扰 RNA(siRNA)沉默 MCF-7 乳腺癌细胞系中的 Efp,以检测其对 14-3-3σ蛋白水平的影响。通过甲基化特异性聚合酶链反应(PCR)评估 14-3-3σ启动子的甲基化状态。用免疫组织化学法检测 220 例人乳腺癌组织中 Efp 和 14-3-3σ的表达。还评估了其他临床病理参数。
沉默 MCF-7 乳腺癌细胞系中的 Efp 导致 14-3-3σ表达增加。Efp 阳性的人乳腺癌组织中 14-3-3σ阴性更为常见(60.5%比 39.5%)。14-3-3σ 的高甲基化很常见(64.9%),与 14-3-3σ阳性呈负相关(p=0.072)。阳性 14-3-3σ 表达与不良预后显著相关:无病生存率(p=0.008)和疾病特异性生存率(p=0.009)。
我们的数据表明,在人乳腺癌中,14-3-3σ 的调节可能涉及两种机制:Efp 介导的泛素化蛋白酶体降解和高甲基化下调。然而,14-3-3σ 的失活可能主要是通过高甲基化实现的。有趣的是,14-3-3σ 是一个非常重要的不良预后指标,这与它先前作为肿瘤抑制因子的功能相反,表明 14-3-3σ 在乳腺癌中可能发挥不同的作用。